merged_ftc-pharmacy-benefit-managers-drug-prices.txt
<other>I need to carefully read through the article to find specific answers to each question, being careful not to infer beyond what is directly stated.</other>

<question_number>1</question_number>
<answer>N/A</answer>

<other>The article states that "The F.T.C. has so far stopped short of bringing a lawsuit or other enforcement action against a benefit manager" so they have not actually brought a lawsuit yet.</other>

<question_number>2</question_number>
<answer>N/A</answer>

<other>The article mentions that CVS Health's Caremark is one of the largest benefit managers and that "By the end of 2018, each had become part of the same company as a giant insurer" but does not specify when CVS Health acquired Caremark.</other>

<question_number>3</question_number>
<answer>N/A</answer>

<other>The article mentions that benefit managers paid their own pharmacies much more than wholesale costs for two generic cancer drugs, resulting in nearly $1.6 billion in revenue for the biggest three conglomerates over less than three years, but this describes revenue to the companies, not overpayment amounts by patients specifically.</other>